The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

The updated labeling for Qelbree provides additional information on the pharmacodynamic profile of the drug. Findings show ...

One out of 7 adults with heart failure were prescribed a medication that could exacerbate their condition. For patients with heart failure (HF), a greater focus on medication management may be ...

A Prescription Drug User Fee Act target date of May 27, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...

The study included 6713 participants who were receiving at least one year of obesity treatment and who were followed until 18 to 30 years. HealthDay News — A positive response to treatment for ...

The outbreak includes 60 active cases in Wyandotte County and seven in Johnson County, according to the Kansas Department of Health and Environment. HealthDay News — Kansas health officials are ...

A phase 3 trial evaluating sotatercept-csrk (Winrevair™) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...